Literature DB >> 9472413

Persisting sensitization of the behavioural response to formalin-induced injury in the rat through activation of serotonin2A receptors.

F V Abbott1, Y Hong, P Blier.   

Abstract

Serotonin potentiates pain induced by intraplantar injection of other inflammatory mediators through the 5-hydroxytryptamine2A receptor, and 5-hydroxytryptamine2A antagonists dose-dependently block pain induced by formalin. The present study examined the temporal characteristics of 5-hydroxytryptamine-mediated potentiation of pain in the rat. Simultaneous injection of the 5-hydroxytryptamine2 receptor agonist alpha-methyl-5-hydroxytryptamine (10 micrograms) plus prostaglandin E2 (0.1 microgram) produced 10 min of lifting and licking of the injected paw. When alpha-methyl-5-hydroxytryptamine was injected before prostaglandin E2, the response decreased as the interval increased, and by 1 h, it was not different from injection of prostaglandin E2 alone. When prostaglandin E2 was injected prior to alpha-methyl-5-hydroxytryptamine, sensitization to the latter persisted for more than 3 h. It was blocked by the 5-hydroxytryptamine2 antagonist ketanserin (5 micrograms), injected locally 5 min before alpha-methyl-5-hydroxytryptamine. Ketanserin (5 micrograms) or the 5-hydroxytryptamine1A/2A antagonist spiperone (0.3 microgram), injected locally 5 min before alpha-methyl-5-hydroxytryptamine and prostaglandin E2, reduced pain by 80-90%, but only by 40-50% when injected 2 min after. Formalin produced a biphasic pain response. The 5-hydroxytryptamine2 antagonists, ketanserin (50 micrograms), spiperone (3 micrograms) and ritanserin (50 micrograms) injected 5 min before formalin reduced the pain response by 70, 90 and 74%, respectively, but only by 40, 30 and 24% when injected at the beginning of the second phase. Pretreatment of the paw with 2 micrograms indomethacin did not alter the response to alpha-methyl-5-hydroxytryptamine plus prostagladin E2, indicating that the sensitization was not due to prostaglandin synthesis. These data show that 5-hydroxytryptamine sensitizes tissue to the pain-producing actions of other inflammatory mediators, and that the sensitization produces a persisting change in tissue that can be blocked by pretreatment with an antagonist, but not reversed after it has occurred. The data imply that 5-hydroxytryptamine2A antagonists may act prophylactically to prevent the evolution of pain in injured tissue, but do not reduce already-present pain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9472413     DOI: 10.1016/s0306-4522(96)00422-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  6 in total

1.  In vivo evidence for a role of protein kinase C in peripheral nociceptive processing.

Authors:  Adriano L S Souza; Fabrício A Moreira; Karine R Almeida; Caryne M Bertollo; Karina A Costa; Márcio M Coelho
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain.

Authors:  P Blier; F V Abbott
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

Review 3.  Serotonin in pain and analgesia: actions in the periphery.

Authors:  Claudia Sommer
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

Review 4.  Peripheral and central sensitization in fibromyalgia: pathogenetic role.

Authors:  Roland Staud; Michael L Smitherman
Journal:  Curr Pain Headache Rep       Date:  2002-08

Review 5.  Is serotonin hyperalgesic or analgesic?

Authors:  Claudia Sommer
Journal:  Curr Pain Headache Rep       Date:  2006-04

6.  Chronic pain and comorbid depression.

Authors:  Raphael J Leo
Journal:  Curr Treat Options Neurol       Date:  2005-09       Impact factor: 3.972

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.